Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


REMS: Added Expense For Pharma, Increased Opportunity For Vendors

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The first anniversary of REMS is March 25: one year from the effective date of the FDA Amendments Act provisions granting FDA authority to require Risk Evaluation and Mitigation Strategies for drugs that raise safety issues.

You may also be interested in...

Record-Setting REMS: FDA’s Classwide Opioid Program Will Be “Massive”

FDA is starting the process of developing a classwide Risk Evaluation & Mitigation Strategy for potent opioid drug products - with the resulting program expected to be the most extensive REMS required by the agency since the implementation of the FDA Amendments Act

Playing Nice Over REMS: FDA Sees Accutane As Model For Shared Systems

FDA will use the Accutane risk management agreement between Roche and generic drug companies as a guide for implementing the Risk Evaluation & Mitigation Strategy "shared use" provision of the FDA Amendments Act

Can A REMS Block A Generic? Thalomid Could Be Early Test

Celgene's arguments against generics of Thalomid (thalidomide) offer another example of the potentially vast consequences of FDA's new safety powers: The firm is arguing that the complexity of its risk management plan precludes the approval of alternate versions of the product





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts